Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ME Therapeutics HoldingFRA:Q9T 14 Piotroski F-Score is 3 as of Aug. 26, 2026, which is at its 10-year median of 3.00. GuruFocus rates FRA:Q9T with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 1,341 Biotechnology companies, ME Therapeutics Holding ranks better than 52.8% on this metric.
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
ME Therapeutics Holding has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for ME Therapeutics Holding's Piotroski F-Score or its related term are showing as below:
FRA:Q9T'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 3 Max: 3
Current: 3
During the past 4 years, the highest Piotroski F-Score of ME Therapeutics Holding was 3. The lowest was 2. And the median was 3.
ME Therapeutics Holding (FRA:Q9T) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
ME Therapeutics Holding Piotroski F-Score Related Terms
ME Therapeutics Holding Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for ME Therapeutics Holding's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:Q9T vs VRTX, REGN, RVMD: Piotroski F-Score Comparison
For the Biotechnology subindustry, ME Therapeutics Holding's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ME Therapeutics Holding Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where ME Therapeutics Holding's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
ME Therapeutics Holding's current Net Income (TTM) was -0.86.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
ME Therapeutics Holding's current Cash Flow from Operations (TTM) was -0.75.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
ME Therapeutics Holding's return on assets of this year was -0.66381988. ME Therapeutics Holding's return on assets of last year was -0.68081344.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
ME Therapeutics Holding's gearing of this year was 0. ME Therapeutics Holding's gearing of last year was 0.01401715.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
ME Therapeutics Holding's current ratio of this year was 3.91489362. ME Therapeutics Holding's current ratio of last year was 12.20430108.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
ME Therapeutics Holding's number of shares in issue this year was 30.049. ME Therapeutics Holding's number of shares in issue last year was 29.589.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
ME Therapeutics Holding's gross margin of this year was . ME Therapeutics Holding's gross margin of last year was .
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
ME Therapeutics Holding's asset turnover of this year was 0. ME Therapeutics Holding's asset turnover of last year was 0.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
1
+
1
+
0
+
0
+
0
+
0
=
3
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
ME Therapeutics Holding has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
ME Therapeutics Holding (FRA:Q9T) has a Piotroski F-Score of 3 as of Aug. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on ME Therapeutics Holding and its competitors. This is near median its historical median of 3.00. Over the past decade, ME Therapeutics Holding's Piotroski F-Score has ranged from 2.00 to 3.00. According to the industry distribution chart, ME Therapeutics Holding ranks #633 out of 1341 companies in the Biotechnology industry, placing it in the top 47.2%.
Is ME Therapeutics Holding's Piotroski F-Score too high?
ME Therapeutics Holding's current Piotroski F-Score of 3 is near median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 3.00. The Biotechnology industry median Piotroski F-Score is 3.00. ME Therapeutics Holding's value of 3 is 0% at this industry median. Based on the distribution chart, ME Therapeutics Holding ranks #633 out of 1341 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ME Therapeutics Holding has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does ME Therapeutics Holding's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ME Therapeutics Holding ranks #633 out of 1341 companies for Piotroski F-Score. This puts ME Therapeutics Holding in the upper half of its industry. The industry median Piotroski F-Score is 3.00. ME Therapeutics Holding's value of 3 is 0% at this benchmark. Historically, ME Therapeutics Holding's own Piotroski F-Score has ranged from 2.00 to 3.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, ME Therapeutics Holding has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,341 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ME Therapeutics Holding's current Piotroski F-Score of 3 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on ME Therapeutics Holding and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ME Therapeutics Holding's current Piotroski F-Score is 3, which is near median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ME Therapeutics Holding stock overvalued right now?
ME Therapeutics Holding (FRA:Q9T) has a current Piotroski F-Score of 3. The current Piotroski F-Score is 3, which is near median its 10-year median of 3.00 and 0% at the Biotechnology industry median of 3.00. ME Therapeutics Holding's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For ME Therapeutics Holding (FRA:Q9T), the current Piotroski F-Score is 3 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ME Therapeutics Holding Inc is a preclinical stage biotechnology company working on cancer-fighting drugs in the field of Immuno Oncology, developing next-generation therapeutics targeting immune suppression in cancer. It is developing novel drugs that target myeloid cells to directly treat cancer and enhance the benefits of current Immuno Oncology drugs, such as checkpoint inhibitors in currently untreatable cancers. Immuno Oncology is a new area of cancer research that has been successful in treating previously untreatable cancers by targeting the immune system rather than the cancer directly, allowing a single drug to be used for multiple cancer types with mostly manageable side effects.
14GF Score
Get the complete analysis for FRA:Q9T
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:Q9T has been successfully added to your 
